9th Annual Biomarkers Congress
Revisiting IBD Management: Dogmas to be Challenged
Sheraton Brussels Hotel
Place Rogier 3 1210 Brussels Belgium
1210 Brussels, Belgium
http://www.drfalkpharma.de/uploads/tx_tocfpshoperw/FS179_Preliminary_Program_new_05.pdf
The field of inflammatory bowel disease is rapidly evolving. Our knowledge of genetic
predisposition, immunological mechanisms and disease behaviour has never expanded as
widely as in the last decade. Our tools to accurately visualize the extent and severity of
inflammation and to detect dysplasia and cancer have become highly reliable. The list of
novel small molecules and biologic agents targeting various mechanisms in the inflammatory
cascade and in the vascular adhesion system is virtually endless.
Yet, many relevant questions remain unanswered when it comes to daily IBD management.
What is the optimal target for disease control? Why does IBD often ‘escape’ despite a time
window of successful response to certain treatments? Why does the disease behaviour
sometimes change drastically during the disease course? Why is postoperative recurrence of
Crohn’s disease virtually inevitable?
Although we have been convinced that we had found many answers to these questions, we
need to realize that many such ‘dogmas’ need to be questioned and readdressed.
The 106th FALK symposium wishes to contribute to this critical attitude vis à vis ‘ancient
beliefs’ in the field of IBD. The era of evidence based medicine forces us to critically review
scientific data, to rephrase certain standards and, above all, to translate novel insights into
the daily care for our patients.
As scientific organizers of this symposium, we hope that you will join us on this exciting
scientific and clinical journey through the world of IBD. We hope to go home with a clearer
view of the intriguing enigma that is IBD.
Registration:
Thursday September 29, 2011
16.00 – 21.00 h
at the congress office

http://www.drfalkpharma.de/uploads/tx_tocfpshoperw/FS179_Preliminary_Program_new_05.pdf

Schedule of Presentations:

Friday, September 30, 2011
08:55:00 Welcome
09:00:00 Dogma 1 – IBD is a disorder of defective autophagy and innate immunity Jack Satsangi, Silvio Danese
09:05:00 Introduction Silvio Danese
09:10:00 Evidence from genetics for the role of autophagy and innate immunity in pathogenesis of IBD Miles Parkes
09:40:00 Bacterial interactions with innate mucosal immunity Elke Cario
10:05:00 Endoplasmatic reticulum stress and inflammation Arthur Kaser
10:30:00 How can innate immunity be stimulated or “corrected”? Francesco Pallone
10:55:00 Wrap-up Jack Satsangi
11:00:00 Coffee break with poster session
11:15:00 Dogma 2 – No bacteria, no IBD Martine de Vos, Arlette Darfeuille-Michaud
11:20:00 Introduction
11:25:00 Lessons from diversion studies and antibacterial interventions Jonathan M. Rhodes
11:45:00 Pouchitis and the role of bacteria in prevention and treatment of IBD Bo Shen
12:05:00 The role of anti(myco)bacterial interventions in the current management of IBD: Is there evidence at all? Jean-Frédéric Colombel
12:30:00 The gut microbiome in health and IBD:Targets for the future? Jeroen Raes
12:55:00 Wrap-up Martine de Vos
13:00:00 Lunch break with poster session
13:55:00 Dogma 3 – TNF plays a pivotal role in IBD Herbert Tilg, Paul Rutgeerts
14:00:00 Introduction
14:20:00 Is efficacy of anti-TNF therapy really related to neutralisation of TNF and apoptosis? G. R. van den Brink
14:30:00 Mechanisms of relapse and loss of response to anti-TNF treatment Matthieu Allez
14:55:00 Anti-TNF therapy in CD and UC: Similar diseases, similar efficacy? Remo Panaccione
15:15:00 Therapeutic alternatives after failure of anti-TNF treatment for IBD Jack Satsangi
15:35:00 Wrap-up Herbert Tilg
15:40:00 Coffee break with poster session
15:55:00 Dogma 4 – Steroids are useful for the management of IBD Stephen B Hanauer
16:00:00 Introduction Stephen B Hanauer
16:05:00 Do steroids have an adverse effect on IBD outcome and healing? Gert van Assche
16:25:00 Pathophysiological changes during steroid treatment for IBD Yehuda Chowers
16:50:00 Steroids with biologicals: Allies or enemies? Brian G. Feagan
17:15:00 Novel steroid formulations: Higher efficacy, less toxicity? Silvio Danese
17:40:00 Wrap-up
17:45:00 End of afternoon session
Saturday, October 1, 2011
08:25:00 Dogma 5 – Early and late Crohn’s disease are distinct entities Janneke van der Woude, Gerassimos Mantzaris
08:30:00 Introduction Janneke van der Woude
08:35:00 Epidemiology of transition from early to late Crohn’s disease Edouard Louis
08:55:00 Markers that differentiate early from late IBD Subra Kugathasan
09:20:00 Can fibrosis be prevented in Crohn’s disease? Miquel Sans Cuffi
09:45:00 Can we slow down evolution from early to late CD? Stuart Schreiber
10:10:00 Wrap-up Gerassimos Mantzaris
10:15:00 Coffee break with poster session
10:40:00 Dogma 6 – Innovative treatments will offer a better outcome for patients with IBD Simon P.L. Travis, Stuart Schreiber
10:45:00 Introduction Simon P.L. Travis
10:50:00 Biologic therapies: Lessons from MS Sarbani Ghosh
11:15:00 Current status of mesenchymal stem cell and bone marrow transplantation in IBD Daan W. Hommes
11:35:00 Resetting the mucosal immune system: Dream or reality? Thomas T. MacDonald
12:00:00 Old wine in new bags: 5-ASA revisited? Axel Dignass
12:25:00 Wrap-up Stuart Schreiber
12:30:00 Lunch break with poster session
13:30:00 Presentation of Poster Prizes
13:35:00 Dogma 7 – Patient tailored therapies are superior to algorithmic approaches in IBD Brian G. Feagan, Filip Baert
13:40:00 Introduction Filip Baert
13:45:00 Predicting the disease course from diagnosis Julián Panés
14:10:00 How to guide therapeutic decisions in a patient-tailored approach? Paul Rutgeerts
14:35:00 Pharmacogenetics and prediction of therapy success Dermot McGovern
15:00:00 Approach to IBD: Treating the disease or the patient? How I do it. Stephen B Hanauer
15:20:00 Wrap-up
15:25:00 Coffee break with poster session
15:50:00 Dogma 8 – Immunosuppression puts IBD patients at risk for severe complications Denis Franchimont, Jean-Frédéric Colombel
15:55:00 Introduction Denis Franchimont
16:00:00 Combined immunosuppression is more dangerous than monotherapy: What is fact and what is rumor Jürgen Schölmerich
16:20:00 Prevention and management of infectious complications in IBD J. F. Rahier
16:40:00 Lymphoma and cancer in IBD: Can they be prevented? Laurent Beaugerie
17:00:00 How to manage IBD in patients with infections or malignancies? Anna Kohn
17:20:00 Wrap-up Jean-Frédéric Colombel
17:20:00 Wrap-up session Leaving the dogmas behind and looking into the future Remo Panaccione, Willem M. de Vos
17:25:00 Towards a novel molecular classification of IBD Severine Vermeire
17:40:00 Towards objective disease measurement Willem M. de Vos
17:55:00 Towards individualized therapeutic approaches in IBD
18:10:00 Toward a “cure” for IBD Claudio Fiocchi
18:30:00 Discussion
18:40:00 End of meeting
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.